Echo Pharmaceuticals

Echo Pharmaceuticals Announces Phase 2 Results for Namisol®, Its' Pipeline Product for Oral Administration of D9-Tetrahydrocannabinol and Appoints The Sage Group

Amsterdam, Cambridge, England And Clinton, New Jersey (ots/PRNewswire) - Echo Pharmaceuticals ("Echo") announces that Namisol(R) has completed successfully a Phase II trial with 24 patients suffering from spasticity and pain due to multiple sclerosis (MS). The trial has been conducted by the Centre for Human Drug ...